Glycobiology/Glycomics Market Size, Share, Growth Analysis and Forecast 2028

Glycobiology/Glycomics Market Size And Industry Analysis

The global glycobiology/glycomics market size was worth USD 962.40 Million in 2021 and is estimated to grow to USD 2157.30 Million by 2028, with a compound annual growth rate (CAGR) of approximately 14.40 Percent over the forecast period. The report analyzes the glycobiology/glycomics market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the glycobiology/glycomics market.

Request Free Sample

Global Glycobiology/Glycomics Market: Overview

Glycomics, also known as glycobiology, studies the structure and function of saccharides found in nature and classified as glycans. Glycan can be found in a variety of species. Glycan is involved in innate immunity, cell regulatory pathways, protein interactions & folding, and cell shape modification. Glycobiology is a rapidly growing natural area with biotechnology, biomedicine, and research applications. After translation, most proteins in eukaryotic cells are changed. Glycan attachment is one of the most prevalent changes in living cells.

N-linked glycosylation, non-enzymatic glycosylated glycoproteins, and O-linked glycosylation are the three types of glycosylation. N-linked glycoproteins are involved in various biological activities, including cell-to-cell recognition, progression, differentiation, and apoptosis induction. The attachment of a sugar moiety to the oxygen atom of a protein's serine or threonine by-products is known as O-linked glycosylation.

Non-enzymatic glycosylation is the harsh chemical attachment of glucose to proteins that occurs when enzymes are not present. Glycobiology has several uses, including diagnostics, cancer, drug creation & development, immunology, and many more. Glycomics is a rapidly growing scientific discipline that focuses on identifying the key characteristics of glycan in biosystems.

Covid-19 Impact:

Pharmaceutical and biotech businesses, in collaboration with governments throughout the world, are striving to solve the COVID-19 epidemic, from vaccine research to planning for pharmaceutical supply chain issues. Approximately 115 vaccine candidates and 155 compounds are now in the R&D pipeline. Furthermore, routinely used medications such as hydroxychloroquine have seen a huge increase in demand for COVID-19 control. Because many wealthy nations are running out of these medications, the rising demand has created enormous potential for developers of COVID-19 management therapies. The pharmaceutical and biotechnology industries are predicted to increase significantly because of the need for COVID-19 vaccines and treatment medications.

Key Insights

• As per the analysis shared by our research analyst, the global glycobiology/glycomics market value is expected to grow at a CAGR of 14.40% over the forecast period.
• In terms of revenue, the global glycobiology/glycomics market size was valued at around USD 962.40 million in 2021 and is projected to reach USD 2157.30 million by 2028.
• Developing pharmaceutical and biopharmaceutical firms The primary reasons driving the glycomics/glycobiology market are technological investments and economic development. The global glycomics/glycobiology market study offers a comprehensive market analysis.
• By product, the instrument category dominated the market in 2021.
• By application, the drug discovery and development category dominated the market in 2021.
• North America dominated the global glycobiology/glycomics market in 2021.

Request Free Sample

Glycobiology/Glycomics Market: Growth Drivers

Developing pharmaceutical and biopharmaceutical firm drives the market.

Technological investments and economic development are the primary reasons driving the global glycomics/glycobiology market. Other enterprises in the sector can benefit from developing countries' strategic advantages. Technological developments are supporting growth due to several government R&D initiatives and drug discovery by biotechnology and pharmaceutical corporations. Furthermore, participation in glycomics and proteomics research projects is rising, which is expected to boost market development throughout the forecast period. Increased sales of medicines used to treat some severe chronic conditions are also expected to stimulate glycomics/glycobiology growth.

Glycobiology/Glycomics Market: Restraints

Higher costs of maintenance and regulation hamper the market growth.

These procedures necessitate the acquisition of necessary components. Regulation and maintenance of these devices are also costly, which may limit the global glycomics/glycobiology market growth throughout the projection period. Bacterial glycomics research has created a novel medicine, glycoconjugate vaccines, and physiologically active glycan. The intrinsic intricacy of glycosylation, as well as its thorough structural examination, is a difficult subject. Technological advancements in glycomics technologies have enabled researchers to understand the importance of glycan in biology, and this trend is expected to continue during the forecast period.

Glycobiology/Glycomics Market: Segmentation

The global glycomics/glycobiology market is segregated based on products, applications, end-user, and regions.

Based on product, the market is segmented into enzymes, instruments, carbohydrates, kits, reagents, and chemicals. Because of their widespread use in drug development and diagnostic testing, instruments commanded the biggest market share. Furthermore, repeated purchases of reagents and kits are projected to drive segment expansion. Because of advances in cancer therapies and detection, enzymes are expected to account for a sizable market share shortly. Glycomics employs a variety of research methods to quantify or characterize the glycomics of a tissue, cell, or organism. Changes in the location or activity of enzymes involved in glycan biosynthesis result in changes in the final glycan structure. As a result, in addition to genetic markers, glycans may be studied to detect environmental changes.

Based on application, the market is classified into disease diagnostics, drug discovery & development, and others. In 2021, drug discovery & development held the biggest market share. This is largely due to considerable R&D and increased government financing for glycomics and proteome research. Other applications are expected to grow faster throughout the projected period, owing to increased clinical trials and R&D costs invested by significant firms for research.

Based on end-user, the market is segmented into pharmaceutical & biotechnology companies, clinical laboratories, and academic research institutes. Academic research institutes accounted for the greatest revenue share in 2021 due to increasing R&D spending. Collaborations between large corporations and research institutes are also helping to expand the industry. Due to increased R&D spending in drug discovery and development and other glycobiology-based studies, the pharmaceutical and biotechnology sector is expected to grow at the fastest CAGR during the projection period.

Glycobiology/Glycomics Market: Regional Landscape

North America dominates the glycobiology/glycomics market.

North America is predicted to be the fastest growing region in the global glycomics/glycobiology market throughout the forecast period. Increased investments in glycomics research, expanded pharmaceutical R&D investment potential for medicine development, and the presence of all main market rivals. North America is expected to dominate the worldwide glycomics market, followed by Europe. Most of North America's share is accounted for by the presence of all important firms, growing funding for glycomics research, expanding R&D spending for pharmaceutical discovery & development, and the presence of all key players. Because of significant pharmaceutical and biopharmaceutical businesses such as Merck KGaA, Agilent Technologies, Danaher, and Thermo Fisher Scientific, North America accounted for the greatest market share in 2021. The regional market has been pushed by well-established healthcare infrastructure and access to innovative goods. Furthermore, government support for R&D activities is a major driver driving glycobiology market expansion in this area.

Due to untapped market prospects, Asia Pacific is predicted to be the second-fastest growing regional market throughout the projection period. The region's glycomics industry has grown dramatically as a result of the region's developing pharmaceutical and biopharmaceutical sectors. Furthermore, Contract Research Organizations (CROs) investments in drug discovery and biologics manufacturing are likely to drive growth in the Asia Pacific glycomics market.

Glycobiology/Glycomics Market: Competitive Landscape

Some of the main competitors dominating the global glycobiology/glycomics market include Agilent Technologies, Waters Corporation, Lectenz Bio, Takara Bio, Thermo Fisher Scientific, Merck KGaA, New England Biolabs, ProZyme, Shimadzu Corporation, and S Bio. 

Global Glycobiology/Glycomics Market Report Scope:

To know more about this report, request a sample copy.

Global Glycobiology/glycomics Market is segmented as follows:

By Product

• Enzymes
• Instrument
• Carbohydrates
• Kits
• Reagents and Chemicals
• Others

By Application

• Disease Diagnostics
• Drug Discovery and Development
• Others

By End-User

• Pharmaceutical and Biotechnology Companies
• Clinical Laboratories
• Academic Research Institutes

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa